Close Menu

NEW YORK (360Dx) – Specific Diagnostics announced today that CARB-X has awarded $1.7 million in second-stage funding for development of its Reveal rapid antibiotic susceptibility test (AST) instrument, based on the firm achieving development and testing milestones.

Mountain View, California-based Specific Diagnostics said that the additional funding will enable its preparation for clinical trials this year. It is readying the system for regulatory validation to enable its launch and use in hospitals.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.